Bayer Aktiengesellschaft (XTRA:BAYN) agreed to acquire Vividion Therapeutics, Inc. for $2 billion on August 5, 2021. Under the terms of the agreement, Bayer will pay an upfront consideration of $1.5 billion and potential success-based milestone payments of up to $500 million. Closing of the transaction is contingent on customary closing conditions, including receipt of the required regulatory approvals, and is expected to take place in Q3 2021.

Credit Suisse Securities (USA) LLC acted as financial advisor and Baker McKenzie acted as legal advisor to Bayer. Centerview Partners acted as financial advisor and Wilson Sonsini Goodrich & Rosati, P.C. and Cooley LLP acted as legal advisors to Vividion. The Cooley Team was led by Barbara Borden (Picture) and Karen Deschaine.

Additional assistance was provided by Kay Chandler, Alessandra Murata, Todd Gluth, Jeffrey Tolin, Megan Browdie, Philip Mitchell and David Navetta.